Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Nanion Starts Shipping the SyncroPatch 384 Patch Engine

Published: Tuesday, September 24, 2013
Last Updated: Tuesday, September 24, 2013
Bookmark and Share
SyncroPatch is a revolutionary instrument for giga-seal, automated patch clamp-based ion channel drug screening.

The brand-new SyncroPatch 384 Patch Engine (PE) now released by Nanion Technologies propels ion channel drug discovery to a new level. Designed for seamless integration into process-automated drug screening environments, the Patch Engine is equipped with 384 patch clamp amplifiers and an advanced 384 channel liquid handling robot.

The SyncroPatch 384PE is the high quality, automated patch clamp system able to finally thrust gold standard electrophysiology from secondary to primary ion channel drug screening. Allowing for up to 20,000 data points per day, it is the most efficient platform on the market for high quality, ion channel recordings. This efficiency is primarily due to fully parallel measurements from 384 cells, the 384-channel pipettor, and an exceptionally efficient control and analysis software. Both hardware and software have been fully tested and validated with leading players in industrial ion channel drug development to provide optimum performance in true HTS for ion channel screening. Designed for seamless integration into process-automated drug screening environments, the Patch Engine is equipped with 384 patch clamp amplifiers and an advanced 384 channel liquid handling robot.

In contrast to prior automated patch clamp devices, which are stand-alone machines, the Patch Engine is a modular approach specifically designed for integration with all aspects of process-automated screening environments. Up to two of the 384 channel patch clamp modules can be integrated into one liquid handling robot, enabling 768 recording wells to be measured simultaneously. Success rates are routinely over 85%, and liquid consumption is low. A full run of 384 cells for dose response analysis takes less than 15 minutes, delivering several thousand data points per hour.

Dr. Niels Fertig, CEO of Nanion says:
“The SyncroPatch 384PE is a landmark in the history of automated patch clamping. It follows a completely revolutionary concept: a truly modular and HTS-capable automated patch clamp device that will integrate into your existing or planned screening process line, rather than being a closed, stand-alone system. No other platform on the market is capable of recording 384 to 768 cells in parallel, let alone with giga-seals.  In development, we have carefully listened to key customers from industrial pharma high throughput screening laboratories to fulfil their requirements of HTS-settings.  We are extremely excited and enthusiastic about our new platform, and so are the first customers who recently invested in several SyncroPatch PE instruments. We are happy to announce that we are now taking orders for delivery in 2013 of this maturely developed and fully validated platform.“

The SyncroPatch 384PE has successfully been validated with a wide variety of different cell types and ion channels, with consistently high performance regarding seal quality and stability. The excellent success rates and cell-stability promote efficient and reliable drug screening, thus minimizing the need of replicate experiments. The SyncroPatch 384PE is now fully available for sale, with the first systems being shipped during the coming month.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nanion Opens US-office in New Jersey
Nanion expands its presence in the American market by the opening of its new headquarters to continue giving customer service.
Wednesday, February 18, 2009
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos